Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 3.01
RMD's Cash to Debt is ranked higher than
78% of the 315 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.11 vs. RMD: 3.01 )
RMD' s 10-Year Cash to Debt Range
Min: 0.69   Max: No Debt
Current: 3.01

Equity to Asset 0.75
RMD's Equity to Asset is ranked higher than
82% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. RMD: 0.75 )
RMD' s 10-Year Equity to Asset Range
Min: 0.35   Max: 0.84
Current: 0.75

0.35
0.84
Interest Coverage 66.09
RMD's Interest Coverage is ranked higher than
78% of the 212 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.30 vs. RMD: 66.09 )
RMD' s 10-Year Interest Coverage Range
Min: 26.38   Max: 9999.99
Current: 66.09

26.38
9999.99
F-Score: 7
Z-Score: 10.27
M-Score: -2.44
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 25.54
RMD's Operating margin (%) is ranked higher than
95% of the 311 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.14 vs. RMD: 25.54 )
RMD' s 10-Year Operating margin (%) Range
Min: -25.07   Max: 28.66
Current: 25.54

-25.07
28.66
Net-margin (%) 22.03
RMD's Net-margin (%) is ranked higher than
95% of the 311 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.12 vs. RMD: 22.03 )
RMD' s 10-Year Net-margin (%) Range
Min: 7.5   Max: 22.2
Current: 22.03

7.5
22.2
ROE (%) 20.61
RMD's ROE (%) is ranked higher than
94% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.62 vs. RMD: 20.61 )
RMD' s 10-Year ROE (%) Range
Min: 7.94   Max: 26.85
Current: 20.61

7.94
26.85
ROA (%) 14.84
RMD's ROA (%) is ranked higher than
96% of the 316 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.40 vs. RMD: 14.84 )
RMD' s 10-Year ROA (%) Range
Min: 5.76   Max: 21.63
Current: 14.84

5.76
21.63
ROC (Joel Greenblatt) (%) 50.98
RMD's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 315 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.59 vs. RMD: 50.98 )
RMD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -44.93   Max: 68.56
Current: 50.98

-44.93
68.56
Revenue Growth (%) 10.80
RMD's Revenue Growth (%) is ranked higher than
85% of the 284 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.10 vs. RMD: 10.80 )
RMD' s 10-Year Revenue Growth (%) Range
Min: 10.8   Max: 31.8
Current: 10.8

10.8
31.8
EBITDA Growth (%) 11.50
RMD's EBITDA Growth (%) is ranked higher than
81% of the 240 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.10 vs. RMD: 11.50 )
RMD' s 10-Year EBITDA Growth (%) Range
Min: 5.9   Max: 81.7
Current: 11.5

5.9
81.7
EPS Growth (%) 18.40
RMD's EPS Growth (%) is ranked higher than
84% of the 244 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.60 vs. RMD: 18.40 )
RMD' s 10-Year EPS Growth (%) Range
Min: 0   Max: 65.8
Current: 18.4

0
65.8
» RMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

RMD Guru Trades in Q3 2013

Jim Simons 692,100 sh (New)
Jeremy Grantham 86,800 sh (+39.23%)
Jean-Marie Eveillard 22,000 sh (unchged)
Paul Tudor Jones Sold Out
Chuck Royce 46,400 sh (-2.52%)
John Hussman 315,000 sh (-10%)
Joel Greenblatt 25,192 sh (-55.27%)
Steven Cohen 9,804 sh (-82.53%)
» More
Q4 2013

RMD Guru Trades in Q4 2013

Chase Coleman 1,000,000 sh (New)
Paul Tudor Jones 17,019 sh (New)
Joel Greenblatt 234,887 sh (+832.39%)
Steven Cohen 15,093 sh (+53.95%)
Chuck Royce 46,800 sh (+0.86%)
Jean-Marie Eveillard 22,000 sh (unchged)
Jeremy Grantham 86,471 sh (-0.38%)
Jim Simons 619,800 sh (-10.45%)
John Hussman 235,000 sh (-25.4%)
» More
Q1 2014

RMD Guru Trades in Q1 2014

Joel Greenblatt 530,016 sh (+125.65%)
Jeremy Grantham 170,814 sh (+97.54%)
Chuck Royce 46,800 sh (unchged)
Jean-Marie Eveillard 22,000 sh (unchged)
Chase Coleman 1,000,000 sh (unchged)
Steven Cohen Sold Out
John Hussman Sold Out
Paul Tudor Jones 10,683 sh (-37.23%)
Jim Simons 14,800 sh (-97.61%)
» More
Q2 2014

RMD Guru Trades in Q2 2014

Chuck Royce 48,333 sh (+3.28%)
Jeremy Grantham 175,314 sh (+2.63%)
Chase Coleman 1,000,000 sh (unchged)
Jean-Marie Eveillard Sold Out
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Joel Greenblatt 18,321 sh (-96.54%)
» More
» Details

Insider Trades

Latest Guru Trades with RMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 Reduce -96.54%0.35%$44.43 - $53.76 $ 52.225%18321
Jean-Marie Eveillard 2014-06-30 Sold Out $44.43 - $53.76 $ 52.225%0
John Hussman 2014-03-31 Sold Out 0.79%$42.03 - $47.82 $ 52.2216%0
Joel Greenblatt 2014-03-31 Add 125.65%0.2%$42.03 - $47.82 $ 52.2216%530016
John Hussman 2013-12-31 Reduce -25.4%0.23%$45.36 - $57.11 $ 52.223%235000
Joel Greenblatt 2013-12-31 Add 832.39%0.23%$45.36 - $57.11 $ 52.223%234887
Joel Greenblatt 2013-09-30 Reduce -55.27%0.06%$43.26 - $54.36 $ 52.228%25192
John Hussman 2013-06-30 Reduce -30%0.26%$44.02 - $51.17 $ 52.2210%350000
Joel Greenblatt 2013-06-30 Add 149.57%0.07%$44.02 - $51.17 $ 52.2210%56317
John Hussman 2013-03-31 Add 66.67%0.34%$41.57 - $48.37 $ 52.2218%500000
Joel Greenblatt 2013-03-31 Reduce -39.33%0.04%$41.57 - $48.37 $ 52.2218%22566
John Hussman 2012-12-31 New Buy0.33%$38.82 - $42.77 $ 52.2228%300000
Joel Greenblatt 2012-12-31 Add 63.18%0.03%$38.82 - $42.77 $ 52.2228%37193
Joel Greenblatt 2012-09-30 Reduce -60.79%0.08%$30.63 - $40.47 $ 52.2249%22793
John Hussman 2012-06-30 Sold Out 0.21%$30.12 - $34.64 $ 52.2264%0
Joel Greenblatt 2012-06-30 Add 165.27%0.08%$30.12 - $34.64 $ 52.2264%58134
John Hussman 2012-03-31 Reduce -26.62%0.05%$24.81 - $31.99 $ 52.2292%350000
Joel Greenblatt 2011-12-31 New Buy0.07%$23.46 - $31.7 $ 52.2291%21376
Jean-Marie Eveillard 2011-12-31 Add 120%$23.46 - $31.7 $ 52.2291%22000
Jean-Marie Eveillard 2011-09-30 Add 25%$25.76 - $33.17 $ 52.2275%10000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 21.70
RMD's P/E(ttm) is ranked higher than
87% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 35.10 vs. RMD: 21.70 )
RMD' s 10-Year P/E(ttm) Range
Min: 16.9   Max: 66.2
Current: 21.7

16.9
66.2
P/B 4.20
RMD's P/B is ranked higher than
65% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.94 vs. RMD: 4.20 )
RMD' s 10-Year P/B Range
Min: 2.29   Max: 5.94
Current: 4.2

2.29
5.94
P/S 4.80
RMD's P/S is ranked higher than
62% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.99 vs. RMD: 4.80 )
RMD' s 10-Year P/S Range
Min: 2.78   Max: 6.93
Current: 4.8

2.78
6.93
PFCF 24.40
RMD's PFCF is ranked higher than
89% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 119.29 vs. RMD: 24.40 )
RMD' s 10-Year PFCF Range
Min: 13.43   Max: 284.56
Current: 24.4

13.43
284.56
EV-to-EBIT 16.60
RMD's EV-to-EBIT is ranked higher than
87% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.34 vs. RMD: 16.60 )
RMD' s 10-Year EV-to-EBIT Range
Min: 12.4   Max: 48.5
Current: 16.6

12.4
48.5
PEG 1.50
RMD's PEG is ranked higher than
94% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. RMD: 1.50 )
RMD' s 10-Year PEG Range
Min: 0.64   Max: 5.64
Current: 1.5

0.64
5.64
Shiller P/E 30.30
RMD's Shiller P/E is ranked higher than
87% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 224.21 vs. RMD: 30.30 )
RMD' s 10-Year Shiller P/E Range
Min: 24.72   Max: 67.17
Current: 30.3

24.72
67.17
Current Ratio 5.77
RMD's Current Ratio is ranked higher than
88% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.78 vs. RMD: 5.77 )
RMD' s 10-Year Current Ratio Range
Min: 1.65   Max: 6.19
Current: 5.77

1.65
6.19
Quick Ratio 5.16
RMD's Quick Ratio is ranked higher than
91% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.82 vs. RMD: 5.16 )
RMD' s 10-Year Quick Ratio Range
Min: 1.24   Max: 5.23
Current: 5.16

1.24
5.23

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.00
RMD's Dividend Yield is ranked higher than
97% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.44 vs. RMD: 2.00 )
RMD' s 10-Year Dividend Yield Range
Min: 0.41   Max: 2.14
Current: 2

0.41
2.14
Dividend Payout 0.42
RMD's Dividend Payout is ranked higher than
91% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. RMD: 0.42 )
RMD' s 10-Year Dividend Payout Range
Min: 0.32   Max: 0.42
Current: 0.42

0.32
0.42
Yield on cost (5-Year) 2.00
RMD's Yield on cost (5-Year) is ranked higher than
92% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. RMD: 2.00 )
RMD' s 10-Year Yield on cost (5-Year) Range
Min: 0.41   Max: 2.14
Current: 2

0.41
2.14
Share Buyback Rate 2.80
RMD's Share Buyback Rate is ranked higher than
94% of the 244 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.30 vs. RMD: 2.80 )
RMD' s 10-Year Share Buyback Rate Range
Min: 2.8   Max: -19.8
Current: 2.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 24.20
RMD's Price/Net Cash is ranked higher than
89% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. RMD: 24.20 )
RMD' s 10-Year Price/Net Cash Range
Min: 11.81   Max: 284.8
Current: 24.2

11.81
284.8
Price/Net Current Asset Value 11.20
RMD's Price/Net Current Asset Value is ranked higher than
87% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. RMD: 11.20 )
RMD' s 10-Year Price/Net Current Asset Value Range
Min: 6.67   Max: 90
Current: 11.2

6.67
90
Price/Tangible Book 5.10
RMD's Price/Tangible Book is ranked higher than
72% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.47 vs. RMD: 5.10 )
RMD' s 10-Year Price/Tangible Book Range
Min: 1.5   Max: 32.9
Current: 5.1

1.5
32.9
Price/DCF (Projected) 1.50
RMD's Price/DCF (Projected) is ranked higher than
86% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.65 vs. RMD: 1.50 )
RMD' s 10-Year Price/DCF (Projected) Range
Min: 1.43   Max: 20.13
Current: 1.5

1.43
20.13
Price/Median PS Value 1.10
RMD's Price/Median PS Value is ranked higher than
78% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. RMD: 1.10 )
RMD' s 10-Year Price/Median PS Value Range
Min: 0.49   Max: 2.57
Current: 1.1

0.49
2.57
Price/Peter Lynch Fair Value 1.20
RMD's Price/Peter Lynch Fair Value is ranked higher than
97% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. RMD: 1.20 )
RMD' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.97   Max: 6.74
Current: 1.2

0.97
6.74
Price/Graham Number 2.20
RMD's Price/Graham Number is ranked higher than
86% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.05 vs. RMD: 2.20 )
RMD' s 10-Year Price/Graham Number Range
Min: 1.01   Max: 14.66
Current: 2.2

1.01
14.66
Earnings Yield (Greenblatt) 6.00
RMD's Earnings Yield (Greenblatt) is ranked higher than
86% of the 316 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.30 vs. RMD: 6.00 )
RMD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.1   Max: 8.1
Current: 6

2.1
8.1
Forward Rate of Return (Yacktman) 19.69
RMD's Forward Rate of Return (Yacktman) is ranked higher than
93% of the 274 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.28 vs. RMD: 19.69 )
RMD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 12   Max: 31.2
Current: 19.69

12
31.2

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:RMD.Australia, RME.Germany, RMEA.Germany, RSMDF.USA
ResMed Inc. a Delaware corporation was formed in March 1994. The Company is a developer, manufacturer and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. Sleep-disordered breathing, or SDB, includes obstructive sleep apnea, or OSA, and other respiratory disorders that occur during sleep. When it was formed in 1989, its primary purpose was to commercialize a treatment for OSA developed by Professor Colin Sullivan. This treatment, nasal Continuous Positive Airway Pressure, or CPAP, was the first successful noninvasive treatment for OSA. CPAP systems deliver pressurized air, typically through a nasal mask, to prevent collapse of the upper airway during sleep. Since the development of CPAP, it has developed a number of innovative products for SDB and other respiratory disorders including airflow generators, diagnostic products, mask systems, headgear and other accessories. The Company's portfolio of products for the treatment of OSA and other forms of SDB includes airflow generators, diagnostic products, mask systems, headgear and other accessories. It produces CPAP, VPAP and AutoSet systems for the titration and treatment of SDB. The flow generator systems deliver positive airway pressure through a patient interface, either a small nasal mask, nasal pillows system, or full-face mask. Mask systems are one of the most important elements of SDB treatment systems. Masks are a primary determinant of patient comfort and as such might drive or impede patient compliance with therapy. It currently markets its products using a network of distributors, independent manufacturers' representatives and its direct sales force. The markets for its products are highly competitive. In the United States, its main market, Philips BV, who acquired Respironics Inc., a previous competitor; DeVilbiss, a division of Sunrise Medical Inc.; Nellcor Puritan Bennett, a division of Covidien Ltd.; and Fisher & Paykel Healthcare Corporation Limited are the primary competitors for its products. The Company's main European competitors are also Philips, DeVilbiss, and Nellcor Puritan Bennett, as well as regional European manufacturers. The Company's products are subject to extensive regulation particularly as to safety, efficacy and adherence to FDA Quality System Regulation, and related manufacturing standards.
» More Articles for RMD

Headlines

Articles On GuruFocus.com
These 7 Growth Stocks Have Potential To Make You Rich Sep 14 2014 
Buy ResMed and Sleep Tight (Like Jim Simons) Feb 02 2014 
3 Cheap Health Care Dividend Stocks with Huge Potential to Grow Dividends Oct 02 2013 
Meeting the Herd Mar 25 2013 
The Best Yielding Ex-Dividend Stocks on February 14, 2013 Feb 13 2013 
Weekly CEO Sells Highlight: ResMed Inc., Chuy’s Holdings Inc., Electronics for Imaging Inc., Coher Feb 04 2013 
ResMed - Growing Business with Consistent Cash Flow Generation at Lowest 10-Year Valuation Jan 24 2012 
predictable hussma Sep 30 2011 
Weekly CFO Sells Highlight: RMD, CATM, HXL, BCR, AMRC Jul 24 2011 
You'll Sleep Better with ResMed in Your Portfolio Jun 26 2011 


More From Other Websites
RESMED INC Files SEC form 10-Q, Quarterly Report Oct 31 2014
Nintendo to develop "quality of life" device to track sleep, fatigue - CEO Oct 29 2014
Urgent need to diagnose cases of sleep apnoea drives homecare device innovation Oct 29 2014
ResMed Posts In-Line Earnings on Revenue Beat in Q1 Oct 27 2014
Strength Seen in ResMed (RMD): Stock Gains 9.1% Oct 27 2014
Asia stocks mixed as Ebola, China concerns offset US gains Oct 24 2014
Resmed sleep machine has dream run Oct 24 2014
Australian shares rise, led by banks; NY Ebola reports temper gains Oct 23 2014
ResMed meets 1Q profit forecasts Oct 23 2014
ResMed meets 1Q profit forecasts Oct 23 2014
RESMED Inc. Announces Results for the First Quarter of Fiscal Year 2015 Oct 23 2014
ResMed Inc Earnings Call scheduled for 4:30 pm ET today Oct 23 2014
RESMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... Oct 23 2014
RESMED Inc. Announces Results for the First Quarter of Fiscal Year 2015 Oct 23 2014
Q1 2015 ResMed Inc Earnings Release - After Market Close Oct 23 2014
ResMed myAir™ Patient Engagement Platform Supports and Coaches Patients to Improve Compliance Oct 21 2014
ResMed myAir™ Patient Engagement Platform Supports and Coaches Patients to Improve Compliance Oct 21 2014
ResMed Enhances U-Sleep Patient Management Platform With Action View For Easier Management By... Oct 21 2014
ResMed Enhances U-Sleep Patient Management Platform With Action View For Easier Management By... Oct 21 2014
ResMed Launches ResMed Data Exchange Oct 20 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK